Molecule-based cytometry method, system and device

The method automates the classification and diagnosis of abnormal cells by generating graphical representations of normal populations, addressing the limitations of current flow cytometry by enhancing sensitivity and specificity in detecting abnormal phenotypes and residual disease without patient-specific panels.

WO2026236358A1PCT designated stage Publication Date: 2026-11-12HEMATOLOGICS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026896
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current flow cytometry techniques for characterizing heterogeneous cell populations require time-consuming data analysis by trained professionals and are limited by the need for patient-specific panels, which can be impractical in clinical settings and fail to detect unexpected abnormalities.

Method used

A method involving multi-dimensional analysis using flow cytometry generates graphical representations of normal cell populations, allowing automated classification and diagnosis of abnormal cells by superimposing test set data onto defined normal populations, enabling rapid identification of abnormal phenotypes without patient-specific reagents.

Benefits of technology

This approach enhances sensitivity and specificity in detecting abnormal cells, reduces processing time, and standardizes analysis across different sites, facilitating the identification of subtle changes in hematopoietic abnormalities and enabling consistent detection of residual disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026896_12112026_PF_FP_ABST
    Figure US2026026896_12112026_PF_FP_ABST
Patent Text Reader

Abstract

For a plurality of sets of normal cells, a respective number of cells of multiple types of cells is determined using flow cytometry, and a mean number of the type of cell for the plurality of sets of normal cells is determined. A graphical representation of a defined normal cell population is generated based on the determined mean numbers. Each cell in the test set of biological cells is classified using flow cytometry based on staining of the test set of cells using the first protocol. A graphical representation of the classification of the cells of the test set of cells is superimposed onto the graphical representation of the defined normal cell population. Cancer may be diagnosed based on the superimposed representation of the cells of the test set of cells onto the graphical representation of the defined normal cell population, and a treatment protocol determined.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MOLECULE-BASED CYTOMETRY METHOD, SYSTEM AND DEVICE BACKGROUND

[0002] Technical Field

[0003] This disclosure is directed to multi-dimensional analysis of measured cell characteristics and in particular to a method, system, device and article for detecting abnormal cells in a test set of cells using multi-dimensional analysis of cell characteristics measured using flow cytometry.

[0004] Description of the Related Art

[0005] One method for characterizing heterogeneous cell populations is by flow cytometry, originally developed by Herzenberg and co-workers (Science. 1969 166(906):747-9; J Histochem Cytochem. 197624(1):284-91; Clin Chem. 1973 19(8):813-6; Ann. N.Y. Acad, of Sci. 1975254:163-171). Using this technology, cells are labeled with antibodies conjugated to dyes. Flow cytometry can routinely detect 3, 4 or more immunofluorescent markers simultaneously in a quantitative manner. By combining multiple immunofluorescent labels with the light scattering properties of the cells it is possible to distinguish not only between cells of different lineages but between cells at various stages of maturation within those lineages. This is determined based on expression patterns of unique cell surface antigens (See for example, Loken MR, etal., in Flow Cytometry in Hematology. Laerum OD, Bjerksnes R. eds.

[0006] Academic Press, New York, pp 31-42, 1992; Civin CI, et al., in "Concise Reviews in Clinical and Experimental Hematology" Martin J. Murphy ed. AlphaMed Press, Dayton OH, 1992, pp 149-159). Populations identified by the flow cytometer can then be isolated using the cell sorting electronics available on the instrument.

[0007] Multi-parameter flow cytometry is currently used to detect a variety of leukemias. However, current techniques require that time consuming data analysis be performed by a professional, namely someone well versed in both flow cytometry and hematopathology, such as a doctor. There is a long learning process required to educate a professional to make the distinction between normal and abnormal cell populations. In addition, when flow cytometry is used to monitor a patient’s response to therapy,conventional techniques require the use of patient-specific panels for detecting residual disease.

[0008] BRIEF SUMMARY

[0009] In an embodiment, a method of characterizing a test set of biological cells is provided. For each set of a plurality of sets of normal cells, a respective number of cells of multiple types of cells in the set of normal cells is determined using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol. For each type of cell of the multiple types of cells, a mean number of the type of cell for the plurality of sets of normal cells is determined. A graphical representation of a defined normal cell population is generated based on the determined mean numbers. The graphical representation includes a representation of each type of the multiple types of cells having a size determined based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells. Each cell in the test set of biological cells is classified using flow cytometry based on staining of the test set of biological cells using the first protocol. A graphical representation of the classification of the cells of the test set of biological cells is superimposed onto the graphical representation of the defined normal cell population.

[0010] In an embodiment, the method includes diagnosing cancer based on the superimposed graphical representation of the classification of the cells of the test set of cells onto the graphical representation of the defined normal cell population. In an embodiment, the method includes determining a treatment protocol to be employed for a patient associated with the test set of cells based on the diagnosis.

[0011] In an embodiment, a computer-implemented method is employed to characterizing a test set of biological cells. For each set of a plurality of sets of normal cells, a respective number of cells of multiple types of cells in the set of normal cells is determined using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol. For each type of cell of the multiple types of cells, a mean number of the type of cell for the plurality of sets of normal cells is determined. A graphical representation of a defined normal cell population is generated based on the determined mean numbers. The graphicalrepresentation includes a representation of each type of the multiple types of cells having a size determined based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells. Each cell in the test set of biological cells is classified using flow cytometry based on staining of the test set of biological cells using the first protocol. A graphical representation of the classification of the cells of the test set of biological cells is superimposed onto the graphical representation of the defined normal cell population.

[0012] In an embodiment, the computer-implemented method includes diagnosing cancer based on the superimposed graphical representation of the classification of the cells of the test set of cells onto the graphical representation of the defined normal cell population. In an embodiment, the computer-implemented method includes determining a treatment protocol to be employed for a patient associated with the test set of cells based on the diagnosis.

[0013] BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0015] Figure l is a functional block diagram of a system implementing an embodiment of a method of diagnosing cancer based on a test set of cells.

[0016] Figure 2 is a schematic diagram of a data structure suitable for storing data related to a set of biological cells.

[0017] Figure 3 is a schematic diagram of a data structure suitable for storing information related to processing of data contained in the data structure illustrated in Figure 2.

[0018] Figures 4 to 10 are illustrations of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, such as the system illustrated in Figure 1, and illustrate populations identified based on staining normal sets of cells using the various antibody combinations.

[0019] Figure 11 illustrates mean and standard deviation information obtained for example identified lineages and maturation stages for a defined normal cell population based on 49 normal bone marrow specimens.Figures 12 and 13 are conceptual diagrams illustrating example graphical representations of a defined normal cell population based on determined mean frequencies of cell types of the defined normal cell population, with the size of each representative cell type population reflecting the proportion of the population in a normal bone marrow specimen.

[0020] Figures 14, 15, and 16 are conceptual diagrams illustrating superimposing graphical representations of the results of classification of cells of test sets of cells onto a graphical representation of a defined normal cell population.

[0021] Figure 17 is a conceptual diagram illustrating another graphical representation of a defined normal cell population based on determined mean frequencies of cell types of the defined normal cell population, with the size of each representative cell type population reflecting the proportion of the population in a normal bone marrow specimen.

[0022] Figure 18 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, and illustrate populations identified based on staining a patient set of cells using various antibody combinations according to a determined protocol.

[0023] Figure 19 is a conceptual diagram illustrating superimposing graphical representations of the results of classification of cells of test sets of cells onto the graphical representation of a defined normal cell population of Figure 17.

[0024] Figure 20 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, and illustrate populations identified based on staining a patient set of cells using various antibody combinations according to a determined protocol.

[0025] Figure 21 is a conceptual diagram illustrating superimposing graphical representations of the results of classification of cells of test sets of cells of Figure 20 onto the graphical representation of a defined normal cell population of Figure 17.

[0026] Figure 22 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, and illustrate populations identified based on staining a patient set of cells using various antibody combinations according to a determined protocol.Figure 23 is a conceptual diagram illustrating superimposing graphical representations of the results of classification of cells of test sets of cells of Figure 22 onto the graphical representation of a defined normal cell population of Figure 17.

[0027] Figure 24 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, and illustrate populations identified based on staining a patient set of cells using various antibody combinations according to a determined protocol.

[0028] Figure 25 is a conceptual diagram illustrating superimposing graphical representations of the results of classification of cells of test sets of cells of Figure 24 onto the graphical representation of a defined normal cell population of Figure 17.

[0029] Figures 26, 27 and 28 are conceptual diagrams illustrating superimposing graphical representations of the results of classification of cells of test sets of cells onto the graphical representation of a defined normal cell population of Figure 17.

[0030] Figure 29 is a flow diagram illustrating an example method of comparing a test set of patient cells to a normal cell population.

[0031] Figure 30 is a conceptual diagram illustrating an example method that may be employed by a diagnostic system to process cells of a test set of cells in order to superimpose a graphical representation of the test set of cells onto a graphical representation of a defined normal population of cells.

[0032] Figure 31 is a flow diagram illustrating an example method or subroutine to perform quality control checks.

[0033] DETAILED DESCRIPTION

[0034] In the following description, certain details are set forth in order to provide a thorough understanding of various embodiments of devices, systems, methods and articles. However, one of skill in the art will understand that other embodiments may be practiced without these details. In other instances, well-known structures and methods associated with, for example, flow cytometers, controllers, etc., such as power supplies, transistors, memory, logic gates, buses, etc., have not been shown or described in detail in some figures to avoid unnecessarily obscuring descriptions of the embodiments.Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as “comprising,” and “comprises,” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.”

[0035] Reference throughout this specification to “one embodiment,” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment,” or “in an embodiment” in various places throughout this specification are not necessarily referring to the same embodiment, or to all embodiments. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments to obtain further embodiments.

[0036] The headings are provided for convenience only, and do not interpret the scope or meaning of this disclosure.

[0037] The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not drawn to scale, and some of these elements are enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn are not necessarily intended to convey any information regarding the actual shape of particular elements, and have been selected solely for ease of recognition in the drawings.

[0038] Gene products can be identified on the cell surface or in the cytoplasm of cells using specific monoclonal antibodies. Flow cytometry can be used to detect multiple immunofluorescent markers simultaneously in a quantitative manner. The technique of immunofluorescent staining is well known and can be carried out according to any of a variety of protocols, such as those described in Current Protocols in Cytometry (John Wiley & Sons, NY, NY, Eds. J. Paul Robinson, etal. . Generally, a biological sample, such as peripheral blood, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, spleen tissue, tumor tissue, and the like, is collected from a subject and cells are isolated therefrom using techniques known in the art. In one embodiment, blood or bone marrow is collected from a subject. A consistent volume of specimen (usually 100 lOOpl) is incubated with antibodies (e.g., monoclonal antibodies) conjugated to any of a variety of dyes (fluorophores) known in the art (see for example,http: / / www.glenspectra.co.uk / glen / filters / fffluorpn.htm or http: / / cellscience.bio-rad.com / fluorescence / fluorophoradata.htm). Representative dyes in this context include, but are not limited to, FITC (Fluorescein Isothiocyante), R-phycoerythrin (PE), Allophycocyanin (APC), Cy7®, and peridinin chlorophyll protein.

[0039] After a period of incubation with a dye-conjugated antibody, typically about 20 minutes in the dark (incubation times and conditions may vary according to particular protocols), mature erythrocytes as lysed using warm (37° C) buffered NH4C1 for 5 minutes. The leukocytes are washed with buffered saline and resuspended in buffered saline containing protein and fixed with paraformaldehyde for introduction into a flow cytometer.

[0040] The flow cytometer analyzes the heterogeneous cell population one cell at a time and can classify the cells based on the binding of the immunofluorescent monoclonal antibody and the light scattering properties of each cell (see, for example, Immunol Today. 200021 (8):383-90). Fluorescence detection is accomplished using photomultiplier tubes or avalanche photo diodes; the number of detectors (channels) determines the number of optical parameters the instrument can simultaneously examine while bandpass filters ensure that only the intended wavelengths are collected. Thus, flow cytometry can routinely detect multiple immunofluorescent markers in a quantitative manner and can measure other parameters such as forward light scatter (which is an indication of cell size) and right angle light scatter (which is an indication of cell granularity). Accordingly, a wide variety of cell populations can be identified and classified using immunofluorescence and flow cytometry.

[0041] For example, by combining 4 colors of immunofluorescence with the physical parameters of forward light scatter (measure of cell size) and right angle light scatter (measure of cell granularity), a six dimensional data space can be generated wherein specific cell populations found in normal blood or bone marrow are restricted to small portions of the data space. As would be recognized by the skilled artisan after reviewing the specification, more or less than 4 colors of immunofluorescent markers could also be used. Excitation of fluorophores is not limited to light in the visible spectrum; several dyes, such as the Indo series (for measuring intracellular calcium) and the Hoechst series (for cell-cycle analyses) are excitable in the ultraviolet range. Thus, some instruments currently available in the art are configured with ultraviolet-emittingsources, such as the four-laser, 10-color Becton Dickinson LSR II. Further, using a commercially available fluorescence activated cell sorter, such as the FACSVANTAGE™ (Becton Dickinson, San Jose, CA), the EPICS® ALTRA™ (Beckman Coulter, Fullerton, CA) or the MOFLO® sorter (DakoCytomation, Inc., Carpinteria, CA) cell populations can also be sorted into purified fractions.

[0042] Gene expression observed during the development of blood cells from hematopoietic stem cells to mature cells found in blood is a highly regulated process. See Civin CI, Loken MR: Cell Surface Antigens on Human Marrow Cells: Dissection of Hematopoietic Development Using Monoclonal Antibodies and Multiparameter Flow Cytometry, Int’l J. Cell Cloning 5:1-16 (1987), which is incorporated herein by reference in its entirety. Thus, specific, tightly controlled expression of genes occurs within not only different lineages of blood cells but also during different stages of maturation within those lineages. See Loken, MR, Terstappen LWMM, Civin Cl, Fackler, MJ: Flow Cytometry Characterization of Erythroid, Lymphoid and Monomyeloid Lineages in Normal Human Bone Marrow, Flow Cytometry in Hematology, Laerum OD, Bjerksnes R. eds., Academic Press, New York, pp. 31-42 (1992), which is incorporated herein by reference in its entirety. Not only do these gene products appear and / or disappear at precise stages of maturation, but the amounts of these glycoproteins are regulated within very tight limits in normal cells. It has been shown that these antigenic relationships are established early in fetal development and are constant throughout adult life on blood cells that are undergoing constant turnover and replenishment. See LeBein TW, Wormann B, Villablanca JG, Law CL, Shah VO, Loken MR: Multiparameter Flow Cytometric Analysis of Human Fetal Bone Marrow B Cells, Leukemia 4:354-358 (1990), which is incorporated herein be reference in its entirety. These patterns and relationships of gene expression during maturation of normal cells are maintained following chemotherapy or even bone marrow transplantation. See Wells DA, Sale GE, Shulman HE, Myerson D, Bryant E, Gooley T, Loken MR: Multidimensional Flow Cytometry of Marrow Can Differentiate Leukemic Lymphoblasts From Normal Lymphoblasts and Myeloblasts Following Chemotherapy and / or Bone Marrow Transplant, Am. J. Clin. Path. 110:84-94 (1998), which is incorporated herein by reference in its entirety. Therefore, there is a very tightly coordinated regulation of multiple genes during normal development of bloodcells both in terms of timing of expression as well as regulation of amounts of gene products expressed on the cell surfaces.

[0043] A comparison of normal antigen expression to neoplastic processes indicates that regulation of gene expression is disrupted in neoplastic cells. This disruption gives rise to different antigenic relationships than those observed during normal maturation of cells. See Hurwitz, CA, Loken MR, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI: Asynchronous Antigen Expression in B Lineage Acute Lymphoblastic Leukemia, Blood, 72:299-307 (1998). These are not new antigens, but are those normally expressed gene products that have lost the coordinated regulation found in normal cells. Both acute lymphoblastic leukemia (“ALL”) and acute myeloblastic leukemia (“AML”) express antigens abnormally. See Terstappen LWMM, Loken MR:

[0044] Myeloid Cell Differentiation in Normal Bone Marrow and Acute Myeloid Leukemia Assessed by Multi-Dimensional Flow Cytometry, Anal. Cell Path. 2:229-240 (1990), which is incorporated herein by reference in its entirety. The types of abnormalities include:

[0045] (1) Lineage infidelity, defined as the expression of non-lineage antigens; (2) Antigenic asynchrony, e.g., the expression on mature cells of antigens that normally appear on immature cells, or the expression on immature cells of antigens that normally appear on mature cells;

[0046] (3) Antigenic absence; and

[0047] (4) Quantitative abnormalities.

[0048] See Terstappen LWMM, Konemann S, Safford M, Loken MR, Zurlutter K, Buchner Th, Hiddemann W, Wormann B: Flow Cytometric Characterization of Acute Myeloid Leukemia, Part II. Phenotypic Heterogeneity at Diagnosis, Leukemia 6:70-80 (1991), which is incorporated herein by reference in its entirety.

[0049] Not only are phenotypes of leukemic cells different from normal, the relationships between antigens are different from one case to the next, suggesting that each leukemic transformation causes a loss of coordinated gene regulation resulting in a unique phenotypic pattern for each leukemia. In 120 pediatric ALL cases and 86 adult AML cases each detailed phenotype was different from normal and from each other. See Id.,- Hurwitz, supra. Thus, neoplastic transformation affects primary DNA sequence (genotype) and the regulation of normal genes so that they are inappropriatelyexpressed at the wrong time during development, expressed in the wrong amounts, and / or are expressed in context with other genes that are not observed in normal cells (phenotype). The loss of coordinated gene regulation appears to be a hallmark of neoplastic transformation that results in abnormal phenotypes where each leukemic clone is different from normal and is different from other leukemias of the same type.

[0050] It should be noted that embodiments are not limited to the analysis of leukemic cells (e.g., acute and chronic lymphocytic leukemias (ALL, CLL) and acute and chronic myelogenous leukemia (AML, CML)) and other hematopoietic and lymphoid neoplastic cells. Embodiments can be applied to analysis of any of a variety of malignancies, e.g., lymphoma, myeloma or pre malignancies such as myelodysplasia, and other disorders, including any of a variety of hematologic disorders.

[0051] Flow cytometry can be adopted to use this phenotypic difference from normal to aid in the diagnosis of leukemia as well as in monitoring response to therapy. Flow cytometry has been used in hematopathology to phenotype the tumor, e.g., differentiating AML from ALL. However, conventional approaches require that the cells of interest form a predominant portion of the total cells examined and that the expected disease process be known before the analysis is performed, such as when a morphologic examination identifies a leukemic cell population of uncertain subtype. The focus on neoplastic cells can extend to residual disease detection. However, conventional residual disease detection techniques employing flow cytometry require a patient specific reagent panel to identify the specific phenotype observed at diagnosis. See Reading CI, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O’Brien MC, Baron S, Deisseroth AB, Expression of Unusual Immunophenotype Combinations in Acute Myelogenous Leukemia, Blood 81:3083-3090 (1993). Such patient specific panels have been used to detect residual ALL and AML down to levels of 0.03-0.05%. See Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D, Clinical Importance of Minimal Residual Disease in Childhood Acute Lymphoplastic Leukemia, Blood 96:2691-2696 (2001); San Miguel JF, Vidriales MB, Lopez-Berges C, DiazMediavilla J, Gutierrez N, Canizo C, Ramos F, Calmunitia MJ, Perez J, Gonzalez M, Orfao A, Early Immunophenotypical Evaluation of Minimal Residual Disease in AcuteMyeloid Leukemia Identifies Different Patient Risk Groups and may Contribute to Postinduction Treatment Stratification, Blood 98:1746-1751 (2002).

[0052] Conventional detection of residual disease using patient specific reagent panels, however, suffers from the following limitations:

[0053] 1. A diagnostic specimen with an aberrant phenotype is required in order to construct a panel. In 25% of cases an aberrant phenotype may not be identifiable. See Vidriales, supra.

[0054] 2. Processing time is substantial because a technician must examine prior analysis for the particular patient in order to determine the reagent combination to use in each case.

[0055] 3. The phenotype of a leukemic cell population that is different than the originally diagnosed phenotype may not be detected. For example, the phenotype may change from diagnosis to relapse as a result of clonal evolution or an outgrowth of a minor chemotherapy resistant subclone. See San Miguel, supra.

[0056] 4. Unexpected or unanticipated abnormalities, such as secondary myelodysplasia or abnormalities in other lineages may be overlooked.

[0057] The assessment of residual disease using patient specific panels can work well in a controlled environment, such as a research study where there is access to all sequential specimens and there is high compliance in obtaining specimens at specific times in therapy. In clinical practice, however, a flow cytometry laboratory may be asked to perform residual disease analysis when the laboratory did not perform the initial diagnosis. A detailed immunophenotype is often unavailable or incomplete.

[0058] Residual disease detection can also be performed using standardized panels and difference from normal as the tumor specific marker. Coordinated gene expression is so precise that a divergence of U a decade in antigen expression is sufficient for the discrimination between normal and aberrant neoplastic cells. In such an approach, specific reagent panels are used for each suspected lineage, for example, B lineage ALL; T lineage ALL; AML; B lineage non-Hodgkins lymphoma (“B-NHL”) and T lineage NHL (“T-NHL”), as well as MDS and myeloma. Tumor populations can be identified by first identifying patterns expected of normal cells, then focusing on cells that do not match the patterns expected of normal cells. This approach of detecting residual disease has been used by the Fred Hutchinson Cancer Research Center forseveral years and has been successful in predicting outcomes in hematopoietic neoplasms. For example:

[0059] 1. In hematopoietic stem cell transplants for ALL, flow cytometry was shown to be more sensitive and more specific than morphology, cytogenetics, or the two technologies combined, in predicting relapse for 120 patients. See Wells, DA, supra.

[0060] 2. In pediatric AML flow cytometric detection of residual disease was the best predictor of outcome in 252 patients studied. Sievers, E. L., Lange, B. J., Alonzo, T. A., Gerbing, R. B., Bernstein, I. D., Smith, F. O., Arceci, R. J., Woods, W. G., Loken, M. R., Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children’s Cancer Group study of 252 patients with acute myeloid leukemia, Blood 101: 3398-3406 (2003). Patients with detectable tumor at any time during therapy were 4 times more likely to relapse and 3 times more likely to die than those patients in whom no tumor was detected.

[0061] 3. The definition of clinical remission has changed from morphology to difference from normal flow cytometry as used by the Children’s Oncology Group. See Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23;120(8): 1581-8. doi: 10.1182 / blood-2012-02-408336. Epub 2012 May 30. PMID: 22649108; PMCID: PMC3429302; Lisa Eidenschink Brodersen, Robert B. Gerbing, M. Laura Pardo, Todd A. Alonzo, Dana Paine, Wayne Fritschle, Fan-Chi Hsu, Jessica A. Pollard, Richard Aplenc, Samir B. Kahwash, Betsy Hirsch, Susana Ramondi, Denise Wells, E. Anders Kolb, Alan S. Gamis, Soheil Meshinchi, and Michael R. Loken.

[0062] Morphologic remission status is limited compared to DN flow cytometry: a Children’s Oncology Group AAML0531 report. Blood Advances, 2020 Oct 27; 4(5050-5061). DOI 10.1182 / bloodadvances.20200020700.

[0063] 4. In hematopoietic stem cell transplants flow cytometry is able to distinguish between normal regenerating blasts and recurrent tumor based on aberrant antigen expression. See Shulman H, Wells D, Gooley T, Myerson D, Bryant E, Loken M., The biologic significance of rare peripheral blasts after hematopoietic celltransplant is predicted by multidimensional flow cytometry. Am J Clin Path 112:513-523 (1999). Patients can exhibit 20% normal blasts in the blood or may have up to 50% regenerating blasts in the marrow without detection of neoplastic cells.

[0064] The detection of abnormal phenotypes of small populations of cells in blood or bone marrow extends the utility of flow cytometry to other applications beyond simply phenotyping leukemias. Flow cytometry has been used to show that a significant proportion (10%) of patients with a diagnosis of myelodysplasia have been misdiagnosed and have lymphoid, not myeloid abnormalities. See Wells DA, Hall MC, Shulman HE, Loken MR, Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias. Leukemia 12:2015-2023 (1998). Flow cytometry has also allowed the development of a scoring system to stratify patients with myelodysplasia based on the degree of abnormalities detected among the maturing myeloid cells. See Wells, D., Benesch, M, Loken, M., Vallejo, C., Myerson, D., Leisenring, W., Deeg, H., Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation, Blood 102: 394-403 (2003). The patients with myeloid cells that exhibited more aberrancies in gene expression as evidenced by abnormal immunophenotype, had a higher relapse rate and death post stem cell transplant as compared to patients with fewer detectable abnormalities. There was also a high correlation with the International Prognostic Scoring System (IPSS). In addition, a high flow cytometric score divided the Intermediate I group of patients in the IPSS system into statistically significant groups based on relapse post stem cell transplant.

[0065] There are several advantages of tumor detection based on difference from normal.

[0066] 1. The technique does not require a diagnostic specimen for creation of a specific panel.

[0067] 2. The approach allows for rapid processing of specimens in a high volume laboratory with identical panels being used for different patients.

[0068] 3. The results are not affected by a change in phenotype following therapy.

[0069] 4. Proper standardized panel selection permits the detection of unexpected or unanticipated findings that are the result of hematologic abnormalities.Conventional distinction between normal and abnormal cell populations does have significant limitations. Data analysis conventionally must be performed by a professional (MD or PhD well versed in both flow cytometry and hematopathology) and not by a technician, since various clinical situations may indicate if abnormalities observed are normal or abnormal. There is a long learning process required to educate a professional to make the distinction between normal and abnormal cell populations. A well-trained hematopathologist may take 6 months to a year to learn the techniques. Currently, the assessment of normal against abnormal by the professional is based on experience with all the inherent difficulties of a subjective analysis, similar to the training in diagnostic microscopy. It is difficult to extend the analysis to other sites and maintain the same sensitivity and specificity. In difficult cases two or more professionals must come to a consensus for a final diagnosis.

[0070] 5. Regeneration of the normal hematopoietic cells can also be assessed. Normal bone marrow is comprised of multiple lineages each undergoing continuous, steady state maturation. By first assessing normal cells, a statistical measure of what constitutes normal and what constitutes abnormal can be defined. This definition then becomes the standard for analysis. Automating the identification of which cells are within the expected, defined positions of normal will facilitate the teaching of new professionals and technicians as to what is phenotypically abnormal. It will also permit the standardization of analysis at multiple sites providing consistency between analysts in identifying abnormal populations.

[0071] Automating the identification of abnormal cells also allows for increased sensitivity and specificity. Current manual evaluation is performed using four antibodies in combination with forward and right angle light scatter collecting 200,000 events for each tube. A panel consists of between seven and fourteen different tubes each with a different combination of antibodies. Using this current system, tumors can be detected with specificity approaching 100%. See Am. J. Clin. Path. 110:84-94, supra, Blood 98:1746-1751, supra, Blood 101:3398-3406, supra. It is possible for a single professional to analyze and report between 20-30 such cases in a single day. Increasing sensitivity is a limitation under conventional approaches because the professional must spend more time analyzing each case. Automating the identificationof abnormal cells will permit larger data sets (counting more cells) and application of more antibodies, without increasing the time an analyst must spend on each specimen.

[0072] The statistical analysis can be used to identify more subtle changes to hematopoietic abnormalities. This is especially important for analysis of Myelodysplastic Syndrome (“MDS”), where abnormalities are observed in the more mature cells rather than just the immature blasts. Statistical analysis will identify bulges in the tubes or shifts in the centroid line that may denote the abnormal regulation of cells. It may also define regulatory points and rates of progression through the developmental process, enabling a better understanding of the loss of coordinated gene regulation observed during neoplastic transformation.

[0073] Other examples of difference from normal diagnostic approaches are discussed in U.S. Patent No. 8,630,833, which is incorporated by reference herein in its entirety, and in U.S. Patent No. 11,639,936, which is incorporated by reference herein in its entirety.

[0074] Figure 1 is a functional block diagram of a system 100 implementing an embodiment of a system for detecting abnormal cells using multi-dimensional analysis. The system 100 comprises a measurement system 102 and a diagnostic system 104.

[0075] The measurement system 102 measures characteristics of cells in a sample of cells, and as illustrated comprises a flow cytometer 106 and a data formatter 108.

[0076] More than one flow cytometer 106 may be employed, although usually the measurements for a particular sample would be taken with one instrument. For example, as discussed in more detail below, measurements from a normal set of cells may be taken with one flow cytometer, while measurements for a test set of cells may be taken with the same flow cytometer in some embodiments, or may be taken with another flow cytometer in other embodiments. Other measurement devices may be employed in the measurement system 102, such as a microscope (e.g., high throughput microscopy).

[0077] The measurement system 102 may contain a separate data formatter 108 to format the data collected by the measurement system 102. Alternatively, the data formatter 108 may be part of another component of the system 100, such as the flow cytometer 106 or the diagnostic system 104. The data formatter 108 may, for example, format data collected by a flow cytometer 106 into Flow Cytometry Standard FCS 2.0format or another data file format. The measurement system 102 may comprise additional components, such as controllers, memories, discrete circuitry and hardware, and various combinations thereof.

[0078] The diagnostic system 104 analyzes data received from the measurement system 102, as discussed in more detail below. In the embodiment illustrated in Figure 1, the diagnostic system 104 comprises a controller 110, a memory 112, a parser 114, a control input / output interface 116, a data input / output interface 118, a graphics engine 120, a statistics engine 122, a display 124, a printer 126 and a diagnostic system bus 130. The diagnostic system bus 130 may include a power bus, control bus, and status signal bus in addition to a data bus. For the sake of clarity, however, the various diagnostic system buses are illustrated in Figure 1 as the diagnostic system bus 130.

[0079] The diagnostic system 104 may be physically remote from the measurement system 102. The measurement system 102 may be coupled to the diagnostic system 104 via one or more communication links, such as the Internet, an extranet, and / or an intranet or other local or wide area networks. Similarly, components of the diagnostic system 104 may be physically remote from one another and may be coupled together via communication links, such as the Internet, an extranet, and / or an intranet or other local or wide area networks. There may be one or more diagnostic systems each coupleable to one or more measurement systems. The communication links may be wired, wireless, or various combinations thereof.

[0080] The diagnostic system 104 may be implemented in a variety of ways, including as separate subsystems. The diagnostic system 104 may be implemented as a digital signal processor (DSP), an application-specific integrated circuit (ASIC), or the like, or as a series of instructions stored in a memory, such as the memory 112 and executed by a controller, such as the controller 110. Thus, software modifications to existing hardware may allow the implementation of the diagnostic system 104. Various subsystems, such as the parser 114 and the control input / output interface 116, are identified as separate blocks in the functional block diagram of Figure 1 because they perform specific functions that will be described in more detail below. These subsystems may not be discrete units but may be functions of a software routine, which will probably, but not necessarily, be separately callable and hence identifiable elements. Any suitable software or combinations of software may be used toimplement the diagnostic system 104, including, for example, WinList and / or Java implemented with a Java Run Time Environment or a 3-D Java Run Time Environment.

[0081] While the illustrated embodiment denotes a single controller 110, other embodiments may comprise multiple controllers. The memory 112 may comprise, for example, registers, read only memory (“ROM”), random access memory (“RAM”), flash memory and / or electronically erasable read programmable read only memory (“EEPROM”), and may provide instructions and data for use by the diagnostic system 104.

[0082] The diagnostic system 104 may comprise additional components, such as controllers, memories, discrete circuitry and hardware, and various combinations thereof.

[0083] An embodiment is described herein with respect to a study that was conducted of different lineages and maturation stages of bone marrow specimens. Where appropriate, references to Figure 1 are incorporated into the description of the study. As would be understood by the skilled artisan, other cell lineages that can be characterized using the methods described herein may comprise multiple lineages or branched lineages and lineages may be defined into varying numbers of stages of development.

[0084] The publicly available Flow Cytometry Standard FCS 2.0 Specification may be employed to store the measured characteristics of the cells in the samples. Other data formats and data structures may be employed, for example an FCS 1.0 or FCS 3.0 format may be employed. An example data structure 200 for storing a data set is illustrated in Figure 2. With reference to Figures 1 and 2, the parser 114 parsed the header section 202, text section 204, data section 206 and analysis section 208 and collected information, including a parameter name, a total number of data points and data type details. The header section 202 describes the location of the other sections in the data structure 200. The header section 202 contains offset information of starting and ending points for the text 204, data 206 and analysis 208 sections. The text section 204 contains a series of ASCII encoded keyword-value pairs that describe various aspects of the data structure 200. For example, $TOT / 5000 / is a keyword-value pair indicating that the total number of events in the file is 5000 and SPAR gives Total parameter number. The data section 206 contains raw data. Such data is usually in oneof three modes (list, correlated or uncorrelated) described in the text section 204, by, for example, a $M0DE keyword value. The data may be written to the data section 206, for example, in one of four formats (binary, floating point, double precision floating point or ASCII) described by a SDATATYPE keyword value. One common form of data storage is list mode storage in the form of binary integers ($DATATYPE / I / $MODE / L / ). The $PnB set of keywords may specify the bit width for the storage of each parameter. The PnR set of keywords may specify the channel number range for each parameter. For example, $PnB / 16 / $PnR / 1024 / , where n is an integer, may specify a 16-bit field for parameter n and a range for the values of parameter n from 0 to 1023, which corresponds to 10 bits. The analysis section 208 is an optional segment that, when present, may contain the results of data processing. The analysis can also be performed off-line, after the data has been collected and stored in a data structure, such as the data structure 200. In the test study, an analysis section 208 was not used. An analysis section 208, however, could be used to store information defining a centroid line and radius for a data set.

[0085] The data offsets of FCS 2.0 format are given in a properties file. An example properties file 300 is illustrated in Figure 3. The properties file contains a header section 302, which contains information about how to read the properties file 300, a format section 304, which contains information about the format of the data structure 200, and a filter section 306, which contains information the parser 114 can use to filter data stored in the data structure 200. The parser 114 uses the information extracted from the properties file 300 to parse the loaded data structure 200. The properties file 300 can be readily modified to permit the use of various data file formats, such as various Flow Cytometry Standard formats.

[0086] The system 100 may use fluorescence intensity corresponding to various markers to gate the data to identify cells of interest. Various gating techniques may be employed (e.g., manual gating; gating based on statistical clustering techniques; gating based on support vector machines; etc., and various combinations thereof). See, e.g., U.S. Patent No. 8,630,833 and in U.S. Patent No. 11,639,936.

[0087] In the studies, a Lyric Flow Cytometer was calibrated using a Primary Standard RFP-30-5a (single bead) protocol to establish a primary intensity. Daily calibration was applied using a Secondary Standard RCP-30-5a (7 beads) protocol to establish alinearity for all fluorescence channels. Light scatter was established with gluraraldehyde fixed chicken erythrocytes. A monthly cross check with normal blood stained with CD4FITC, CD4PE, CD4PerCP, and CD4APC was employed. Conversion of mean fluorescence intensity (MFI) to number of molecules was based on CD4 being equal to 46,000 molecules. In the studies, the flow cytometer was very stable.

[0088] In one study, cells of normal sets of cells, and cells of test sets of cells, were exposed to the following antibody combinations (FITC = fluorescein isothiocyanate; PE = R Phycoerythrin; PerCP = Peri dinin Chlorophyl Protein; APC = Allophycocyanin):

[0089] FITC PE PerCP APC

[0090] Tube l: CD38 CD117 CD45 CD34

[0091] Tube 2: CD16 CD13 CD45 CD34

[0092] Tube 3: CD36 CD64 CD45 CD34

[0093] Tube 4: HLA-DR CDllb CD45 CD34

[0094] Tube 5: HLA-DR CD123 CD45 CD34

[0095] Tube 6: CD5 CD 19 CD45 CD34

[0096] In a second and a third study, cells of normal sets of cells, and of test sets of cells, were exposed to the following antibody combinations (FITC = fluorescein isothiocyanate; PE = R Phycoerythrin; PerCP = Peridinin Chlorophyl Protein; APC = Allophycocyanin):

[0097] FITC PE PerCP APC

[0098] Tube 1 : None None CD45 CD34

[0099] Tube 2: HLA-DR CDllb CD45 CD34

[0100] Tube 3: CD5 CD 19 CD45 CD34

[0101] Tube 4: CD10 CD38 CD45 CD34

[0102] Tube 5: CD38 CD117 CD45 CD34

[0103] Tube 6: CD16 CD13 CD45 CD34

[0104] Tube 7: CD14 CD33 CD45 CD34

[0105] Tube 8: CD36 CD64 CD45 CD34

[0106] Tube 9 HLA-DR CD 123 CD45 CD34

[0107] Tube 10: CD7 CD56 CD45 CD34

[0108] Using the above combinations, in the second and third studies the entire cellular composition of the bone marrow specimen was obtained, and used to classify 23 cellpopulation in the second study and 24 cell populations in the third study. Other antibody combinations may be employed. The reagent combinations used in the second and third study extend the identifiable populations to mature B, T and NK lymphoid populations, stages 1 and 2 of immature B lymphoid cells, uncommitted progenitor cells, stages 1, 2, 3, 4, and 5 maturing neutrophils, immature and maturing monocytes, plasmocytic dendritic cells, basophils, mast cells, eosinophils, immature and maturing erythroid cells.

[0109] In the studies, antibodies were obtained from Becton Dickinson, as follows:

[0110] Antibody Clone

[0111] HLA-DR FITC L243

[0112] CD5 FITC L17F12

[0113] CD7 FITC 4H9

[0114] CD 10 FITC HI 10a

[0115] CDllb PE ICRF44

[0116] CD13 PE L138

[0117] CD 14 FITC M(|)P9

[0118] CD 16 FITC 3G8

[0119] CD19 PE 4G7

[0120] CD33 PE 67.6

[0121] CD34 APC 8G12

[0122] CD36 FITC CB38

[0123] CD38 FITC HIT2

[0124] CD38 PE HB7

[0125] CD45 PerCP 2D1

[0126] CD56 PE NC AMI 6.2

[0127] CD64 PE 10.1CD117 PE 104D2

[0128] CD 123 PE 9F5

[0129] The specimens were stained, and then analyzed to identify cells of different lineages and maturational stages based on multi-dimensional gating. The flow cytometer was standardized to yield immunofluorescence in terms of numbers of molecules per cell. In the first and second studies, manual gating using large gates was employed. In the third study, gating was performed using support vector machines (SVMs). Other gating methods may be employed (e.g., statistical analysis, artificial intelligence agents, etc., and various combinations thereof). Gating may be established based on the statistical variability around the mean in, for example, a 6D space.

[0130] Previous studies comparing SVM gating to the manual gating showed that the differences were confined to the outer boundaries of the log normally distributed cell populations. Therefore, differences in frequencies were minor and had minimal if any effect on defining the population center (multidimensional mean) or variation around that center (SD). Therefore, the reagent combinations combined with light scattering properties of each cell population of interest can be well separated from all other cells using SVM gating.

[0131] An expert identified and established the 6-dimensional boundaries for all of these cell populations for 49 phenotypically normal bone marrow specimens. These specimens came from post treatment patients who had achieved full regeneration of the marrow specimens after re-establishing steady state hematopoiesis. This analysis of 49 bone marrow specimens resulted in the establishment of normal range values in the studies.

[0132] The population centroid (in 6 dimensional space) as well as the log normal distribution around that mean (SD) were very consistent from individual to individual indicating minimal variability of most gene products as has been shown in our previous work. The frequency of events assigned to each population were also similar.

[0133] In the third study SVMs were created for each cell population by training on one half of the selected specimens then tested on the remaining one half of the selectedspecimens. The SVM values and expert values were then compared showing correlation (R2>0.95).

[0134] Therefore, it is possible to assign events to specific cell populations identified by the expert based on SVM for all hematopoietic cells in a bone marrow specimen. Thus, SVM analysis of flow cytometric data can define the cellular composition of all the normal cells within a bone marrow specimen. These normal range studies can be extended.

[0135] In the second and third studies, the normal sets of cells consisted of 49 separate human bone marrow specimens which were used to define normal ranges for cell types of a normal cell population. The specimens of normal cells were required to have all reportable cell populations of the studies. All of the specimens of normal cells were post-therapy, but normal (e.g., regenerated steady state specimens without detectable neoplastic cells). The specimens were collected to a threshold number of events per specimen (200,000 events in the studies). CD45PerCP and CD34APC were included in all tubes. The gating used a multidimensional approach linking forward and log side scatter, CD45 and CD34, to the FITC and PE labeled antibodies. Proportions and intensities of each cell population were determined for each specimen.

[0136] Figures 4 to 10 are illustrations of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, such as the system illustrated in Figure 1, and illustrate populations identified based on staining the normal sets of cells using the various antibody combinations of the second and third study. Figure 4 shows Progen, Lymph, Mono, and Myeloid cells identified based on the antibody combination of Tube 1. Figure 5 shows Plasma, Progen+Mono, and Mast cells identified based on the antibody combination of Tube 5. Figure 6 shows Common Progenitor, Granular Blasts, Promyelocytes, Myelocytes, Meta / Band and Neutrophils cells identified based on the antibody combination of Tube 6. Figure 7 shows Mono 1, Mono 2, and Erythroblasts cells identified based on the antibody combination of Tube 8. Figure 8 shows Eos cells identified based on the antibody combination of Tube 2. Figure 9 shows Basophils and Plasmocytic Dendritic cells identified based on the antibody combination of Tube 9. Figure 10 shows Lymph (B Lymphocytes, Lymphoblast 3, NK Lymph, and T lymph) cells identified based on the antibody combination of Tube 3.The staining and gating protocols used to classify normal cells (e.g., staining using the various antibody combinations and gating), can be applied to a test set of cells to classify cells of the test set of cells, which can then be compared to the defined normal set of cells. It is noted that a test set of cells may not have enough cells to reach the threshold (e.g., as a result of presence of cancer or due to prior cancer treatment).

[0137] Conventional approaches of data display are limited to small subsets of the types of cells of the cellular composition of a bone marrow specimen, and typically provide information about the test set of cells which cannot be easily interpreted by a practitioner (e.g., an oncologist) to detect cancer or to determine an appropriate course of treatment for a detected cancer based on the analysis of the test set of cells.

[0138] To address this issue a graphic method embodiments have been devised to display very complex data in a manner familiar to the practicing oncologist. The mean frequency, and optionally, a standard deviation, can be determined (e.g., by the system 100 of Figure 1) for each normal cell population identified based on the protocol applied to the normal sets of cells. The determined mean frequencies, and in some embodiments, standard deviations, can be used to define a normal cell population for each of the cell types and displayed relative to the composition of normal bone marrow specimens. The standard deviation of each population can be used, for example, to establish events that exceed three standard deviations from the mean, which for most gene products is 0.5 decades thereby defining the basis of classifying cell populations as normal or abnormal In some embodiments, these events can be excluded if they do not represent a sufficient proportion of cells or if they do not form a distinct cluster of events.

[0139] The mean number of cells for each cell population (in the specimen sample of 200,000 events) can be converted to a relative area to generate a graphical representation of a defined normal cell population for the identified cell population, for example, as discussed in more detail below. The representations of the normal cell populations for the identified cell population types can be arranged in a manner indicative of a maturation level within a cell lineage recognizable by trained physicians.

[0140] The same protocol can be applied to a test set of cells, the test set of cells can be analyzed and classified using the same gating and analysis applied to the normal sets of cells, and a representation of the cell populations of the test set of cells can besuperimposed on the representation of the defined normal population of cell types. This facilitates providing a practitioner with an easy to understand comparison of the characteristics of the test set of cells to the defined normal population of cell types. The practitioner can use the information in the representation, possibly together with additional information, to diagnose cancer and determine a treatment protocol. As noted above, the test set of cells may have less than the threshold number of cells used for the normal sets of cells.

[0141] Figure 11 shows mean and standard deviation information obtained for example identified lineages and maturation stages (cell types) based on the 49 human bone marrow specimens in the second study. Some embodiments may use more than 49 post-therapy normal specimens, and it is noted that the mean and standard deviation (used to define a normal cell population for the cell types) are remarkably stable over time as more post-therapy normal specimens are added to the set of normal specimens used to generate the mean and standard deviation information.

[0142] Figure 12 is a conceptual diagram illustrating an example graphical representation of the defined normal cell population for 23 cell populations based on determined mean frequencies (and, in some embodiments, standard deviations) for the cell populations. Each type of identified normal cell is represented as having an area (or size) determined based on the determined mean frequency for the respective normal cell population. The size of each representative cell-type population in the representation of the normal cell population reflects the proportion of these populations in normal bone marrow specimens.

[0143] Horizontal positioning in Figure 12 generally corresponds to a cell maturation level. In addition, a CD34 line is shown which indicates cells to the left of the CD34 line are CD34 positive, and cells to the right of the line are CD34 negative, denoting very immature cells to the left with further maturation to the right. Similar representations may be provided for other markers. It is noted that the relative areas of the representations of the cell populations of the conceptual diagram of Figure 12 may not be to scale.

[0144] Figure 13 is a conceptual diagram illustrating an example graphical representation of the defined normal cell population similar to Figure 12. In Figure 13, the graphical representation of defined normal cell populations also includescorresponding percentage indicators for some of the cell populations or groups of populations. For example, the Granular Blasts, Promyelocytes, Myelocytes, Meta > Bands, and Neutrophils as illustrated together comprise approximately 67% of the total number of cell in the defined normal cell population. It is noted that the relative areas of the representations of the cell populations of the conceptual diagram of Figure 13 may not be to scale.

[0145] In some embodiments, different colors may be employed in the representation of a normal cell population to distinguish between different cell populations (e.g., lymph cells may be one color, and Eryth Blast cells may be a different color). As illustrated in Figures 12 and 13, labels are used without color.

[0146] Figures 14, 15, and 16 are conceptual diagrams illustrating superimposing graphical representations of the results of classification of cells of test sets of cells onto the graphical representation of a defined normal cell population of Figure 12.

[0147] Figure 14 illustrates an example in which the analysis indicates all of the cells of the test set of cells are normal. As illustrated in Figure 14, blue shading is superimposed on the representations of the cell types of the defined normal cell population to indicate the cells of the test set of cells are classified as normal cells. Other ways of indicating whether cells of the test set of cells are classified as normal cells may be employed (e.g., different colors, hatching, etc.). A practitioner reviewing the diagram of Figure 14 may thus determine that cancer is not detected, and, for example, that no treatment or additional treatment is necessary.

[0148] Figure 15 illustrates an example of a test set of cells with mixed normal and leukemia cells. The Mast, Baso, Dendritic, Eryth Blast, Eos, Common Progenitor, HSC, and B Lymphoblast cell populations of the normal cell population areas are shown as empty, to indicate such cells are missing from the test set of cells of Figure 15. The normal areas are partially filled for the Granular Blasts, Promyelocytes, Myelocytes, Meta>Bands and Neutrophils cells, to indicate less that the normal number of such cells are present in the test set of cells. The areas of the Mature Lymph cells are shown as full, with a percentage indicator of 17%, which is higher than normal (see Figure 13, with a percentage indicator of 11% for normal). In some embodiments, the areas of cells (such as Mature Lymph cells) may be overfilled to indicate the percentage of such cells is higher than normal. It is noted that since lymphocytes are not usuallyaffected by chemotherapy, the proportion of these cells might be used to normalize the entire cell population. A high lymphocyte proportion may represent solely a decrease in the other cells expected in the specimen.

[0149] The diagram of Figure 15 also indicates cancer cells are present is the test set of cells using a different color, shades of red in Figure 15. As illustrated, 65 percent of the total cells in the test set of cells are leukemia cells. The leukemia cells are not homogeneous, but are heterogeneous, and this is indicated using different shades of color, such as different shades of red. As illustrated, the diagram also includes textual information regarding the different types of leukemia cells. A practitioner reviewing the diagram of Figure 15 may thus determine that a non-homogeneous cancer population is detected, and that additional treatment is necessary. Using this information and other information about a patient such as molecular abnormalities or cytogenetics, a treatment protocol may be determined and applied. A graphic illustration at diagnosis may provide insight as to which cell populations remain after therapy in leukemia specimens demonstrating phenotypic heterogeneity.

[0150] It is noted that the position of the leukemia cells in Figure 15 indicates the leukemia cells are CD34 positive (immature cells) by placing the leukemia cells to the left of the CD34 line. The position of the leukemia cells also indicates the leukemia is a mixture of myeloid and lymphoid leukemias. A practitioner may consider different treatment options based on the position of the cancer cells in the graphical representation.

[0151] Figure 16 illustrates an example of a representation of a test set of cells from the same patient represented in Figure 15 with mixed normal and leukemia cells after a course of treatment has been administered, which is superimposed on a representation of a normal cell population. For example, the set of test cells represented in Figure 16 may correspond to a patient treated based on the classification of cells of a test set of cells represented in Figure 15, and other information related to the patient. The Mast, Baso, Dendritic, Eos, Myelocytes, Meta>Bands, Neutrophils, and B Lymphoblasts 2 and 3 normal areas are shown as empty (no blue shading), to indicate such cells are missing from the test set of cells of Figure 16. The normal area is filled for the Common Progenitor, HSC, Eryth Blast, Granular Blasts, Mono 1 and 2, and Promyelocytes Cells. The areas of the Mature Lymph cells are shown as full, which apercentage indicator of 73%, which is substantially higher than normal (see Figure 13, with a percentage indicator of 11% for normal). In some embodiments, the areas of cells (such as Mature Lymph cells) may be overfilled to indicate the percentage of such cells is higher than normal. As noted above, since lymphocytes are not usually affected by chemotherapy, the proportion of these cells might be used to normalize the entire cell population. A high lymphocyte proportion may represent solely a decrease in the other cells expected in the specimen.

[0152] The diagram of Figure 16 also indicates cancer cells are present in the test set of cells using a different color, shades of red in Figure 16. As illustrated, 4.6 percent of the total cells in the test set of cells are leukemia cells. The leukemia cells are not homogeneous, and this is indicated using different shades of color, such as different shades of red. As illustrated, the diagram also includes textual information regarding the different types of leukemia cells. A practitioner reviewing the diagram of Figure 16 may, for example, determine that while cancer is present, there are some signs of recovery as well (e.g., the presence of the Common Progenitor and Granular Blast cells). In such a case the practitioner may decide treatment may be postponed to allow recovery to proceed (e.g., to allow more Neutrophils to develop, which can reduce the likelihood of infection) before treatment is restarted. If instead there was no indication of leukemia, the practitioner might determine that while no Neutrophils are present, the patient is in an early stage of recovery, and no treatment for Leukemia is needed at this time.

[0153] Figure 17 is a conceptual diagram illustrating another example graphical representation of defined normal cell populations for 24 cell populations based on determined mean frequencies (and, in some embodiments, standard deviations) for the cell populations. Each type of identified normal cell is represented as having an area (or size) determined based on the determined mean frequency for the respective normal cell population defined in the normal range study. The size of each representative celltype population in the representation of the normal cell population reflects the proportion of these populations in normal bone marrow specimens.

[0154] Horizontal positioning in Figure 17 generally corresponds to a cell maturation level. It should be noted that such positioning can be vertical positioning, rather than horizontal positioning. A line defining expression of CD34, a well known marker ofhematopoietic immaturity, is shown which indicates cells to the left of the CD34 line are CD34 positive, and cells to the right of the line are CD34 negative. Similar representations may be provided for other markers. Different colors may be employed in the representation of the normal cell population to distinguish between different cell populations. As illustrated in Figure 17, normal cells which are CD34 positive (to the left of the CD34 line) are shaded red. Normal cells which are CD34 negative (to the right of the CD34 line) are shaded blue, with mature cells shaded in darker than immature cells (e.g., mature neutrophils are a darker blue than stages stages 1, 2, 3, and 4 of maturing neutrophils). It is noted that the relative areas of the representations of the cell populations of the conceptual diagram of Figure 17 may not be to scale.

[0155] Figure 18 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, such as the system illustrated in Figure 1, and illustrate populations identified based on staining a test set of cells using the various antibody combinations of the 10-tube protocol described above. In Figure 18, the data corresponds to a patient in remission with no evidence of leukemia.

[0156] Figure 19 illustrates an example of superimposing a graphical representation of the test set of cells of Figure 18 onto the graphical representation of the defined set of normal cells of Figure 17. Figure 19 shows that the cells of the test set of cells may be generally considered as normal, and uses the same color coding as Figure 17 for the cell populations. The representation of Figure 19, however, also show differences in percentages of cells in the test set of cells from the percentages of cells in the defined set of normal cells. For example, the percentage of CD34 positive cells is shown as 1.0 percent in Figure 19, to indicate the percentage is different from the 3.0 percent for the defined set of normal cells. A practitioner reviewing the graphical representation of Figure 19 may thus determine that cancer is not detected, and, that the patient is in clinical remission.

[0157] Figure 20 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, such as the system illustrated in Figure 1, and illustrate populations identified based on staining a test set of cells using the various antibody combinations of the 10-tube protocol described above. In Figure 20, the data corresponds to a patient who received chemotherapy after a relapse.Figure 21 illustrates an example of superimposing a graphical representation of the test set of cells of Figure 20 onto the graphical representation of the defined set of normal cells of Figure 17. The superimposed graphical representation of Figure 21 shows that the Mature Lymph cells are present in normal numbers, but that all of the other types of cells of the defined set of normal cells are missing. This is indicated in Figure 21 by shading of the Mature Lymph cell regions in blue to indicate the Mature Lymph cells have normal numbers, and by labeling the other cell regions without shading or percentages to indicate the cells of the respective cell types are not present. A practitioner reviewing the graphical representation of Figure 21 may thus determine that post-chemotherapy bone marrow regeneration is not occurring in the patient, however, this is not a result of residual leukemia. The practitioner may thus decide, for example, to recommend administration of growth factors or initiate a bone marrow transplant or other course of treatment.

[0158] Figure 22 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, such as the system illustrated in Figure 1, and illustrate populations identified based on staining a test set of cells using the various antibody combinations of the 10-tube protocol described above. In Figure 22, the data corresponds to a patient in relapse after treatment.

[0159] Figure 23 illustrates an example of superimposing a graphical representation of the test set of cells of Figure 22 onto the graphical representation of the defined set of normal cells of Figure 17. The graphical representation of Figure 23 illustrates an example of a test set of cells with mixed normal and leukemia cells. The Mast, Baso, Dendritic, Eryth Precursors, Eos, Mono 1, Mono 2, Myeloid Progens, Stages 2, 3, 4 and Mature Neutrophils, and B Progen Stages 1, 2, and 3, and plasma cell populations of the normal cell population areas are shown as empty, to indicate such cells are missing from the test set of cells of Figure 23. The areas of the Mature Lymph cells are shown as full, with a percentage indicator of 5%, which is lower than normal (see Figure 17, with a percentage indicator of 11% for normal). In some embodiments, the areas of cells (such as Mature Lymph cells) may be partially filled to indicate the percentage of such cells is lower than normal.

[0160] The diagram of Figure 23 also indicates that CD34 positive cancer cells are present in the test set of cells by shading a region to the left of the CD34 line orange. Asingle shade of orange is used to indicate the cancer cells are homogeneous. As illustrated, the diagram also includes textual information regarding the type of leukemia cells which indicates the cancer cells are Acute Myeloid Leukemia (AML) cells and constitute 92% of the cells. A practitioner reviewing the graphical representation of Figure 23 may thus determine that cancer is detected. The practitioner may thus decide, for example, to recommend or initiate further treatment, such chemotherapy or radiation treatment, or some other course of treatment. It is noted that the position of the leukemia cells in Figure 23 indicates the leukemia cells are CD34 positive (immature cells) by placing the leukemia cells to the left of the CD34 line. The position of the leukemia cells also indicates the leukemia is an immature type with minimal maturation to any specific lineage. A practitioner may consider different treatment options based on the position of the cancer cells in the graphical representation if other clinical tests such as molecular or cytogenetics are also positive.

[0161] Figure 24 is an illustration of multi-dimensional data projected into pseudo two-dimensional displays generated by a system, such as the system illustrated in Figure 1, and illustrate populations identified based on staining a test set of cells using the various antibody combinations of the 10-tube protocol described above. In Figure 24, the data corresponds to a patient with post chemotherapy heterogeneous monocytic leukemia.

[0162] Figure 25 illustrates an example of superimposing a graphical representation of the test set of cells of Figure 24 onto the graphical representation of the defined set of normal cells of Figure 17. The graphical representation of Figure 25 illustrates an example of a test set of cells with mixed normal and leukemia cells. The HSC, Mast, Baso, Dendritic, Eryth Precursors, Early Erythroid, N-RBC, Eos, Myeloid Progens and Stage 2 immature Neutrophils, and B Progen Stages 1, 2, and 3, and plasma cell populations of the normal cell population areas are shown as empty, to indicate such cells are missing from the test set of cells of Figure 25. The areas of the Mature Lymph cells are shown as full, with a percentage indicator of 38%, which is higher than normal (see Figure 17, with a percentage indicator of 11% for normal). In some embodiments, the areas of cells (such as Mature Lymph cells) may be overfilled to indicate the percentage of such cells is higher than normal.

[0163] The diagram of Figure 25 also indicates that CD34 positive leukemia cells are present in the test set of cells by shading a region to the left of the CD34 line orange,and that CD34 negative leukemia cells are predominant, represented by shading a region to the right of the CD34 line green. Two shades of color are used to indicate the cancer cells are heterogeneous. As illustrated, the diagram also includes textual information regarding the type of CD34 negative leukemia cells which indicates the cancer cells are Acute Monocytic Leukemia (AML) cells and constitute 48% of the cells. A practitioner reviewing the graphical representation of Figure 25 may thus determine that heterogeneous leukemia is detected. The practitioner may thus decide, for example, to recommend or initiate further treatment, such chemotherapy or radiation treatment, or some other course of treatment. The position of the leukemia cells also suggests demonstration of maturation from immature forms to more mature cells. A practitioner may consider different treatment options based on the position of the cancer cells in the graphical representation.

[0164] Figure 26 also illustrates an example of a test set of cells with mixed normal and leukemia cells, and is similar to Figure 15, except that the graphical representation of the test set of cells is superimposed on the graphical representation of the defined set of normal cells of Figure 17. The Mast, Baso, Dendritic, Erythroid Precursors, Early Erythroid, N-RBC, Eos, Common Progenitor, HSC, and B Lymphoblast cell populations of the normal cell population areas are shown as empty, to indicate such cells are missing from the test set of cells of Figure 26. The normal areas are partially filled for the Myeloid Progens, the Stage 2, Stage 3, Stage 4, and Mature Neutrophils, to indicate less that the normal number of such cells are present in the test set of cells. The areas of the Mature Lymph cells are shown as full, with a percentage indicator of 17%, which is higher than normal (see Figure 17, with a percentage indicator of 11% for normal). In some embodiments, the areas of cells (such as Mature Lymph cells) may be overfilled to indicate the percentage of such cells is higher than normal. It is noted that since lymphocytes are not usually affected by chemotherapy, the proportion of these cells might be used to normalize the entire cell population. A high lymphocyte proportion may represent solely a decrease in the other cells expected in the specimen.

[0165] The diagram of Figure 26 also indicates cancer cells are present is the test set of cells using different colors, shades of orange in Figure 26. As illustrated, 65 percent of the total cells in the test set of cells are leukemia cells. The leukemia cells are not homogeneous, but are heterogeneous, and this is indicated using different shades ofcolor, such as different shades of orange. As illustrated, the diagram also includes textual information regarding the different types of leukemia cells. A practitioner reviewing the diagram of Figure 26 may thus determine that a heterogeneous leukemia population is detected that has characteristics of both myeloid and lymphoid cells, i.e. a mixed phenotype acute leukemia with subclones. Using this information and other information about a patient, a treatment protocol may be determined and applied. For example, some of the types of leukemia with these characteristics may respond differently to specific chemotherapeutic regimens.

[0166] It is noted that the position of the leukemia cells in Figure 26 indicates the leukemia cells are CD34 positive (immature cells) by placing the leukemia cells to the left of the CD34 line. The position of the leukemia cells also indicates the leukemia is a mixture of myeloid and lymphoid leukemias. A practitioner may consider different treatment options based on the position of the cancer cells in the graphical representation.

[0167] Figure 27 illustrates an example of a representation of a test set of cells from the same patient represented in Figure 26 with a predominance leukemia cells now after a course of treatment has been administered, which is superimposed on a representation of a normal cell population. Figure 27 is similar to Figure 15, except that the graphical representation of the test set of cells is superimposed on the graphical representation of the defined set of normal cells of Figure 17. The Mast, Baso, Dendritic, Eos, Stage 3, Stage 4 and Mature Neutrophils, and B Lymphoblasts 2 and 3 normal areas are shown as empty (no blue shading), to indicate such cells are missing from the test set of cells of Figure 27, suggesting early recovery of normal hematopoiesis. The normal area is filled for the Common Progenitor, HSC, Eryth Blast, Mono 1 and 2, Myeloid Progens and Stage 2 immature Neutrophils. The areas of the Mature Lymph cells are shown as full, with a percentage indicator of 73%, which is substantially higher than normal (see Figure 17, with a percentage indicator of 11% for normal). In some embodiments, the areas of cells (such as Mature Lymph cells) may be overfilled to indicate the percentage of such cells is higher than normal. As noted above, since lymphocytes are not usually affected by chemotherapy, the proportion of these cells might be used to normalize the entire cell population. A high lymphocyte proportion may represent solely a decrease in the other cells expected in the specimen.The diagram of Figure 27 also indicates leukemia cells are present in the test set of cells using a different color, shades of orange in Figure 27. As illustrated, 4.6 percent of the total cells in the test set of cells are leukemia cells. The leukemia cells are not homogeneous, and this is indicated using different shades of color, such as different shades of orange. As illustrated, the diagram also includes textual information regarding the different types of leukemia cells which heterogeneously express both lymphoid and myeloid antigens. A practitioner reviewing the diagram of Figure 27 may, for example, determine that while cancer is present, there are some signs of recovery as well (e.g., the presence of the Common Progenitor, Myeloid Progens and Stage 2 immature Neutrophils cells). In such a case the practitioner may decide treatment may be postponed to allow recovery to proceed (e.g., to allow more Neutrophils to develop, which can reduce the likelihood of infection) before treatment is restarted. If, instead there was no indication of leukemia, the practitioner might determine that while no Neutrophils are present, the patient is in an early stage of recovery, and no treatment for Leukemia is needed at this time.

[0168] Figure 28 illustrates an example of a representation of a test set of cells for a patient in recovery after treatment, which is superimposed on the graphical representation of the defined set of normal cells of Figure 17. The Mast, Baso, Dendritic, Eos, and B Lymphoblasts 1, 2 and 3 normal areas are shown as empty (no blue shading), to indicate such cells are missing from the test set of cells of Figure 28. The normal area is filled for the Common Progenitor, HSC, Eryth Progens, Mono 1 and 2, and is overfilled for the Myeloid Progens and Stage 2 immature Neutrophils. The normal areas are partially filled for the Myeloid Progens, the Stage 2, Stage 3, Stage 4, and Mature Neutrophils, to indicate less that the normal number of such cells are present in the test set of cells. A practitioner reviewing the diagram of Figure 28 may, for example, determine that no cancer is present, and there are significant signs of recovery (e.g., the presence of the Common Progenitor, Myeloid Progens and Stage 2 immature Neutrophils cells). In such a case the practitioner may decide as to whether additional treatment is necessary.

[0169] It is noted that the graphical representation of the classification of cells of the test set of cells superimposed on the representation of the defined normal cell population may also indicate other information useful to the practitioner. For example,a quality of the test specimen may be indicated (e.g., a Hemodiluted specimen, Lymphocyte predominance). In another example, pre-leukemic cells such as those identified in myelodysplastic syndrome may be indicated by the representation of a test set of cells superimposed on the representation of the defined normal cell population. For example, different colors or positions may be used to indicate pre-leukemic cells. In another example, an absolute neutrophil count of the peripheral blood in a patient may be provided in the representation or otherwise used to determine a course of treatment together with the information comparing the representation of cells of the test set of cells to the representation of the defined normal cell population. For example, the timing of a treatment protocol may be determined based on the comparison and the absolute neutrophil count with the representative cell populations present in the bone marrow.

[0170] Figure 29 is a flow diagram illustrating an example subroutine 400 that may be employed by a diagnostic system, such as the diagnostic system 104 illustrated in Figure 1, to superimpose a graphical representation of the classification of cells of a test set of cells onto a graphical representation of a normal cell population. The superimposed graphical representation may be employed to diagnose cancer and determine a treatment protocol based on the diagnosis.

[0171] The subroutine 400 starts at 402, where, for each set of cells of a plurality of sets of normal cells, a respective number of cells of multiple types of cells in the normal set of cells is determined using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol. The first protocol may be, for example, the 6-tube protocol or the 10-tube protocol described above with respect to the studies. Other protocols may be employed. Gating may be employed to group cells into cell types, and once grouped, the number of cells of each cell type may be determined. For example, manual gating by an analyst may be employed, automated gating may be employed (e.g., using SVMs, a trained classifier, etc.), or various combinations thereof. A number of the multiple types of cells can depend on the cell classification scheme employed. For example, as illustrated in Figures 11 and 12, the number of the multiple types of cells can be 23 is some embodiments, and as illustrated in Figure 17, the number of the multiple types of cells can be 24 in other embodiments. The subroutine 400 proceeds from 402 to 404.At 404, the diagnostic system 104 determines, for each type of cell of the multiple types of cells, a mean number of the type of cell for the plurality of sets of normal cells. For example, respective numbers of a type of cell of each set of normal cells are added together and divided by the number of sets of normal cells. The diagnostic system 104 proceeds from 404 to 406.

[0172] At 406, the diagnostic system 104 generates a graphical representation of a normal cell population based on the determined mean numbers. The graphical representation includes a representation of each type of the multiple types of cells having a size based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells. The diagnostic system 104 proceeds from 406 to 408.

[0173] At 408, the diagnostic system 104 classifies each cell in the test set of biological cells using flow cytometry based on staining of the test set of cells using the first protocol. The same gating used at 402 to classify cells of the normal sets of cells can be employed to classify cells of the test set of cells. As noted above, a test set of biological cells may not contain all of the types of cells of a normal set of cells, and may include other types of cells (e.g., cancer cells). Additional or modified gating may be employed to classify other types of cells of the test set of biological cells. The diagnostic system 104 proceeds from 408 to 410.

[0174] At 410, the diagnostic system 104 superimposes a graphical representation of the classification of the test set of cells onto the graphical representation of the normal cell population generated at 406. The superimposed graphical representation includes a representation of types of cells detected in the classification of the cells of the test set of biological cells. The representation of a type of cell detected in the test set of biological cells can have a size based on a number of the detected type of cell in the test set of biological cells, and a position based on the type of detected cell. Other information can be included in the superimposed graphical representation, such as percentages of types of cells, an indication of a Myeloid to Erythroid ratio, etc. Colors may be used in the superimposed graphical representation to indicate types of cells, such as normal or cancer cells. In some embodiments, the diagnostic system 104 proceeds from 410 to 412.At 412, the diagnostic system 104 diagnoses cancer based on the superimposed graphical representation of the classification of the cells of the test set of cells onto the graphical representation of the normal cell population. The diagnosis may be performed automatically (e.g., using a trained classifier or artificial intelligence agent), may be performed based on input from an analyst, or combinations thereof. In some embodiments, the diagnostic system 104 proceeds from 412 to 414.

[0175] At 414, the diagnostic system 104 determines a treatment protocol to be recommended or employed based on the diagnosis. The treatment protocol may be determined automatically (e.g., using a trained classifier or artificial intelligence agent), may be performed based on input from an analyst, or various combinations thereof.

[0176] Some embodiments of a diagnostic system 104 may perform other acts not shown in Figure 29, may not perform all of the acts shown in Figure 29, or may perform the acts of Figure 29 in a different order. For example, the subroutine 400 may may call a subroutine or Figure 31, to determine whether a test set of cells satisfies a quality control criteria, and to trigger an alert or other action in response to a determination that the test set of cells does not satisfy the quality control criteria.

[0177] Figure 30 is a conceptual diagram illustrating an example method 500 that may be employed by a diagnostic system to process cells of a test set of cells in order to superimpose a graphical representation of the test set of cells onto a graphical representation of a defined normal population of cells. For convenience, the method 500 of Figure 30 will be described with reference to the diagnostic system 104 and the flow cytometer 106 of Figure 1.

[0178] The method 500 starts at 502, where the diagnostic system 104 processes bone marrow or blood using a defined reagent panel to stain cells of the test set of cells. The diagnostic system 104 uses a standardized flow cytometer 106 to process the stained cells and provide numbers of molecules for each of the gene products of interest. The number of molecules can be provided as list mode data. The defined protocol is a same defined protocol used to generate the graphical representation of the defined normal population of cells, and the defined representation of the defined normal population of cells also is generated using data from a standardized flow cytometer. Using a defined protocol and a standardized flow cytometer to generate both the graphical representation of the defined normal population of cells and the superimposedrepresentation of a test set of cells facilitates accurately identifying abnormal cells and generating meaningful graphical representations that can be readily understood by a treatment professional, such as an oncologist.

[0179] The method 500 proceeds from 502 to 504. At 504, the diagnostic system 104 analyzes the data obtained at 502 using multiple SVMs to determine frequency positions of normal populations. The SVM boundaries 506 are defined by an expert based on normal bone marrow specimens. The same SVM boundaries may have been used to classify cells to generate the graphical representation of the defined normal population of cells. As noted above, a test set of biological cells may not contain all of the types of cells of a normal set of cells, and may include other types of cells (e.g., cancer cells). Thus, at 504, the diagnostic system 104 classifies the test set of cells as corresponding to normal marrow in response to the analysis indicating all of the expected types of cells are present and within normal population ranges, and the diagnostic system 104 classifies the test set of cells as abnormal marrow in response to one or more of the expected types of cells not being within normal population ranges (e.g., the analysis indicates an expected a type of cell is not found in the test set of cells, or the numbers of such cells are outside an expected range). At 504, the diagnostic system 104 also may analyze the data obtained at 502 for quality control purposes (e.g., to detect low cellularity, hemodilution, low viability, other other indications that the sample should be rejected), and to highlight events for review by an analyst (e.g., events more than 3 standard deviations from a normal range). One or more thresholds may be employed in the analysis by the diagnostic system 104 at 504.

[0180] In response to the analysis at 504 indicating the test set of cells corresponds to normal marrow, the method proceeds from 504 to 508. At 508, the diagnostic system 104 creates a representation of the population frequency relative to the normal population ranges. See, for example, Figures 14 and 19 and the descriptions thereof.

[0181] In response to the analysis at 504 indicating the test set of cells corresponds to abnormal marrow, the method proceeds from 504 to 510. At 510, the diagnostic system 104 creates a representation of the population frequency relative to the normal population ranges as well as a representation of the abnormal populations. See, for example, Figures 15, 16, 21, 23, and 25-28 and the descriptions thereof. The representations of the abnormal populations may be done, for example, based on inputfrom an analyst, automatically (e.g., using a trained classifier or artificial intelligence agent) or combinations thereof.

[0182] Figure 31 is a flow diagram illustrating an example subroutine 600 that may be employed by a diagnostic system, such as the diagnostic system 104 illustrated in Figure 1, to perform quality control checks during the processing of sets of cells, such as processing to classify the cells using flow cytometry data and to generate graphical representation of the classification of cells. For example, the subroutine 600 may be called by acts 402, 404, 406 and 408 of method 400 of Figure 29, or by act 504 of method 500 of Figure 30.

[0183] The subroutine 600 starts at 602, and proceeds to 604. At 604, the subroutine 600 evaluates received flow cytometry data, related analysis, or combinations thereof. For example, flow cytometry data for a tube of the 6-tube or the 10-tube protocols discussed above may be received and evaluated, or analysis based on the cytometry data for a tube, such as interim classification analysis, etc., may be received. In another example, flow cytometry data or analysis from a standardization confirmation protocol (e.g., one or more calibration tubes) may be received. The evaluation may be iterative and consider the existing context as additional flow cytometry data and analysis is received. The subroutine 600 proceeds from 604 to 606.

[0184] At 606, the diagnostic system 104 determines whether the evaluation is consistent with the cytometry data being provided by a standardized flow cytometer. This may be done, for example, by analyzing received flow cytometry data associated with a standardization confirmation protocol to determine whether the evaluation indicates the flow cytometer is operating within the standardization requirements. In another example, this may be done by analyzing received flow cytometry data associated with a test set of cells and detecting an indication that the flow cytometer providing the data is not standardized. In response to determining at 606 that the evaluation is not consistent with the cytometry data being provided by a standardized flow cytometer, the subroutine 600 proceeds from 606 to 614, where error processing may be performed, such as generating an alert indicating the flow cytometer needs to be calibrated or standardized, returning a result of the evaluation to a calling program or subroutine, etc. In response to determining at 606 that the evaluation is consistent withthe cytometry data being provided by a standardized flow cytometer, the subroutine 600 proceeds from 606 to 608.

[0185] At 608, the diagnostic system 104 determines whether the evaluation is consistent with a staining protocol. This may be done, for example, by analyzing received flow cytometry data to determine whether the evaluation indicates the data is consistent with expected data at a particular point in time of a staining protocol. For example, a multitube staining protocol may specify an order in which the flow cytometry results for the tubes is to be processed. If the evaluation indicates flow cytometry results for the tubes is being processed in the wrong order, the diagnostic system 104 may determine the evaluation is not consistent with the multitube staining protocol. In response to determining at 606 that the evaluation is not consistent with the staining protocol, the subroutine 600 proceeds from 608 to 614, where error processing may be performed, such as generating an indication that the flow cytometry results for the tubes is being processed in an incorrect order, returning a result of the evaluation to a calling program or subroutine, etc. In response to determining at 608 that the evaluation is consistent with the staining protocol, the subroutine 600 proceeds from 608 to 610.

[0186] At 610, the diagnostic system 104 determines whether the evaluation indicates the sample quality is acceptable. This may be done, for example, by analyzing received flow cytometry data to determine whether the evaluation indicates the sample quality is insufficient, such as an indication that there is insufficient bone marrow in the sample or an insufficient number of cells in the sample. In response to determining at 610 that the evaluation is not consistent with an acceptable sample quality, the subroutine 600 proceeds from 610 to 614, where error processing may be performed, such as generating an indication that the sample quality is not acceptable, returning a result of the evaluation to a calling program or subroutine, etc. In response to determining at 610 that the evaluation is consistent with an acceptable sample quality, the subroutine 600 proceeds from 610 to 612.

[0187] At 612, the diagnostic system 104 determines whether there is more flow cytometry data or analysis to evaluate. In response to determining at 612 that there is more flow cytometry data or analysis to evaluate, the subroutine 600 returns to 604 to evaluate the additional flow cytometry data or analysis. In response to determining at612 that there is no additional flow cytometry data or analysis to evaluate, the subroutine 600 terminates or performs other processing, such as returning results of the evaluation to a calling program or subroutine.

[0188] Some embodiments of a diagnostic system 104 may perform other acts not shown in Figure 31, may not perform all of the acts shown in Figure 31, or may perform the acts of Figure 31 in a different order. For example, the subroutine 600 may combine acts 604, 606, 608 and 610, or perform acts 606, 608 and 610 in parallel.

[0189] Some embodiments may take the form of or comprise computer program products. For example, according to one embodiment there is provided a computer readable medium comprising a computer program adapted to perform one or more of the methods or functions described above. The medium may be a physical storage medium such as for example a Read Only Memory (ROM) chip, or a disk such as a Digital Versatile Disk (DVD-ROM), Compact Disk (CD-ROM), a hard disk, a memory, a network, or a portable media article to be read by an appropriate drive or via an appropriate connection, including as encoded in one or more barcodes or other related codes stored on one or more such computer-readable mediums and being readable by an appropriate reader device.

[0190] Furthermore, in some embodiments, some or all of the methods and / or functionality may be implemented or provided in other manners, such as at least partially in firmware and / or hardware, including, but not limited to, one or more application-specific integrated circuits (ASICs), digital signal processors, discrete circuitry, logic gates, standard integrated circuits, controllers (e.g., by executing appropriate instructions, and including microcontrollers and / or embedded controllers), field-programmable gate arrays (FPGAs), complex programmable logic devices (CPLDs), state machines, etc., as well as devices that employ RFID technology, and various combinations thereof.

[0191] In an embodiment, a method of characterizing a test set of biological cells is provided. The method includes: for each set of a plurality of sets of normal cells, determining a respective number of cells of multiple types of cells in the set of normal cells using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol; for each type of cell of the multiple types of cells, determining a mean number of the type of cell for the pluralityof sets of normal cells; generating a graphical representation of a defined normal cell population based on the determined mean numbers, wherein the graphical representation includes a representation of each type of the multiple types of cells having a size determined based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells; classifying each cell in the test set of biological cells using flow cytometry based on staining of the test set of biological cells using the first protocol; and superimposing a graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population.

[0192] In an embodiment, a computer-implemented method of characterizing a test set of biological cells is provided. The computer-implemented method includes: for each set of a plurality of sets of normal cells, determining a respective number of cells of multiple types of cells in the set of normal cells using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol; for each type of cell of the multiple types of cells, determining a mean number of the type of cell for the plurality of sets of normal cells; generating a graphical representation of a defined normal cell population based on the determined mean numbers, wherein the graphical representation includes a representation of each type of the multiple types of cells having a size determined based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells; classifying each cell in the test set of biological cells using flow cytometry based on staining of the test set of biological cells using the first protocol; and superimposing a graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population.

[0193] In an embodiment, the superimposed graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population is used to diagnose cancer.

[0194] In an embodiment, the diagnosing cancer comprises diagnosing residual cancer. In an embodiment, a treatment protocol to be employed for a patient associated with the test set of biological cells is determined based on the diagnosis.In an embodiment, the method includes diagnosing cancer based on the superimposed graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population. In an embodiment, the method includes determining a treatment protocol to be employed for a patient associated with the test set of cells based on the diagnosis.

[0195] In an embodiment, the staining of cells using the first protocol comprises exposing the cells to the following antibody combinations: FITC None; PE None, PerCP CD45, and APC CD34; FITC HLA-DR, PE CD1 lb, PerCP CD45, and APC CD34; FITC CD5, PE CD 19, PerCP CD45, and APC CD34; FITC CD 10, PE CD38, PerCP CD45, and APC CD34; FITC CD38, PE CD117, PerCP CD45, and APC CD34; FITC CD16, PE CD13, PerCP CD45, and APC CD34; FITC CD14, PE CD33, PerCP CD45, and APC CD34; FITC CD36, PE CD64, PerCP CD45, and APC CD34; FITC HLA-DR, PE CD123, PerCP CD45, and APC CD34; and FITC CD7, PE CD56, PerCP CD45, and APC CD34, where FITC is fluorescein isothiocyanate, PE is R Phycoerythrin, PerCP is Peridinin Chlorophyl Protein, and APC is Allophycocyanin.

[0196] In an embodiment, a number of the multiple types of cells is 23 types of cells. In an embodiment, a number of the multiple types of cells is 24 types of cells.

[0197] In an embodiment, a type of cell corresponds to: a lineage of the cell; a maturation stage of the cell; or combinations thereof.

[0198] In an embodiment, the types of cells of the multiple types of cells include: Hematopoietic Stem Cells (HSC); Common Progenitor; Mast Cells; Basophils;

[0199] Plasmocytic Dendritic Cells; Erythroblasts; Eosinophils (EOS); Monocyte 1; Monocyte 2; Nucleated Red Blood Cells (N RBC); Granular Blasts cells (Myeloid Progenitor Cells); Promyelocytes cells (Stage 2 Maturing Myeloid Cells); Myelocytes (Stage 3 Maturing Myeloid Cells); Metamyelocytes >Bands cells (Stage 4 Maturing Myeloid Cells); Neutrophils (Mature Neutrophils); B Lymphoid Progenitor Cells 1; B Lymphoid Progenitor Cells 2; B Lymphoid Progenitor Cells 3; Mature Lymphocytes NK; Mature Lymphocytes B; Mature Lymphocytes T; Plasma cells; or combinations thereof.

[0200] In an embodiment, the types of cells of the multiple types of cells include: Hematopoietic Stem Cells (HSC); Common Progenitor Cells; Mast Cells; Basophils; Plasmocytic Dendritic Cells; Erythroid Precursors; Early Erythroid Cells; Nucleated Red Blood Cells (N RBC); Eosinophils (EOS); Monocyte 1; Monocyte 2; MyeloidProgenitors; Stage 2 Immature Neutrophils; Stage 3 Immature Neutrophils; Stage 4 Immature Neutrophils; Neutrophils; B Lymphoid Progenitor 1; B Lymphoid Progenitor 2; B Lymphoid Progenitor 3; Mature Lymphocytes; Mature Lymphocytes NK; Mature Lymphocytes B; Mature Lymphocytes T; Plasma cells; or combinations thereof.

[0201] In an embodiment, a position in the graphical representation of the normal cell population along a horizontal axis is an indicator of a cell maturation level. In an embodiment, a position in the graphical representation of the normal cell population along a vertical axis is an indicator of a cell maturation level.

[0202] In an embodiment, the graphical representation of the normal cell population includes a line (e.g., a horizontal or vertical line) representing a transition in the representation between cell types which are CD34 positive and cell types which are CD34 negative.

[0203] In an embodiment, the graphical representation of the normal cell population includes percentage indicators for one or more of the cell populations or groups of cell populations.

[0204] In an embodiment, the graphical representation of the normal cell population uses color to distinguish different types of cell.

[0205] In an embodiment, superimposing the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population includes using color to indicate cancer cells in the cells of the test set of biological cells.

[0206] In an embodiment, superimposing the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population includes: underfilling an area of a normal cell type to indicate a number of the type of cell in the test set of biological cells is less than the determined mean number of the type of cell for the plurality of sets of normal cells; overfilling an area of a normal cell type to indicate a number of the type of cell in the test set of biological cells is larger than the determined mean number of the type of cell for the plurality of sets of normal cells; or combinations thereof.

[0207] In an embodiment, the method includes: detecting an indication of the presence of one or more types of cancer based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto thegraphical representation of the normal cell population; detecting an indication of the absence of cancer based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population; detecting an indication of a stage of recovery based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population; detecting an indication of a response to treatment based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population; or combinations thereof.

[0208] In an embodiment, the method includes determining a treatment protocol to be employed for a patient associated with the test set of biological cells based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population. In an embodiment, the determined treatment protocol includes: no treatment; waiting; monitoring; chemotherapy; radiation treatment; or combinations thereof.

[0209] In an embodiment, the determining for each set of the plurality of sets of normal cells, a respective number of cells of multiple types of cells in the set of normal cells comprises using gating to classify the cells stained using the first protocol. In an embodiment, the method includes using the gating to classify cells in the test set of biological cells. In an embodiment, the gating is set based on user input; the gating is set using a processing agent; or the gating is set using a processing agent in combination with user input. In an embodiment, the processing agent uses statistical clustering techniques to set the gating; the processing agent uses Support Vector Machines (SVMs) to set the gating; or the processing agent uses statistical clustering techniques and SVMs to set the gating.

[0210] In an embodiment, the method includes: flagging the test data set as indicating normal marrow based on the classifying of each cell in the test set of biological cells; flagging the test data set as indicating abnormal marrow based on the classifying of each cell in the test set of biological cells; flagging the test data set for review; or combinations thereof.In an embodiment, the method includes flagging the test data set of cells for review. In an embodiment, the method includes: flagging the test data set of cells for review in response to an indication the staining is inconsistent with staining using the first protocol; flagging the test data set of cells for review in response to an indication analysis of the cells of the test set of cells was performed incorrectly; flagging the test data set of cells for review in response to an indication the test set of cells includes an insufficient number of cells; flagging the test data set of cells for review in response to an indication the test set of cells was improperly collected; or combinations thereof.

[0211] In an embodiment, a diagnostic system comprises one or more memories, and processing circuitry coupled to the one or more memories, wherein the processing circuitry, in operation, implements one or more of the methods disclosed herein.

[0212] In an embodiment, a non-transitory computer-readable medium’s contents configure a processing system to perform one or more of the methods disclosed herein.

[0213] As would be recognized by the skilled artisan, the above methods can be used in a number of settings, including but not limited to diagnostics and disease and treatment monitoring.

[0214] All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and / or listed in the Application Data Sheet, are incorporated herein by reference, including U.S. Provisional Patent Application No. 63 / 800,951, filed May 6, 2025, unless otherwise stated.

[0215] From the foregoing it will be appreciated that, although specific embodiments have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the disclosure. The above examples are offered by way of illustration and not by way of limitation.

Claims

CLAIMSWhat is claimed is:

1. A method of characterizing a test set of biological cells, the method comprising:for each set of a plurality of sets of normal cells, determining a respective number of cells of multiple types of cells in the set of normal cells using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol;for each type of cell of the multiple types of cells, determining a mean number of the type of cell for the plurality of sets of normal cells;generating a graphical representation of a defined normal cell population based on the determined mean numbers, wherein the graphical representation includes a representation of each type of the multiple types of cells having a size determined based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells;classifying each cell in the test set of biological cells using flow cytometry based on staining of the test set of biological cells using the first protocol; and superimposing a graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population.

2. A computer-implemented method of characterizing a test set of biological cells, the computer-implemented method comprising:for each set of a plurality of sets of normal cells, determining a respective number of cells of multiple types of cells in the set of normal cells using flow cytometry to classify cells of the set of normal cells based on staining of the cells of the set of normal cells using a first protocol;for each type of cell of the multiple types of cells, determining a mean number of the type of cell for the plurality of sets of normal cells;generating a graphical representation of a defined normal cell population based on the determined mean numbers, wherein the graphical representation includes a representation of each type of the multiple types of cells having a size determined based on the determined mean for the type of cell and having a position based on the type of cell of the multiple types of cells;classifying each cell in the test set of biological cells using flow cytometry based on staining of the test set of biological cells using the first protocol; and superimposing a graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population.

3. The method of any of the proceeding claims, wherein the superimposed graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population is used to diagnose cancer.

4. The method of claim 3, wherein diagnosing cancer comprises diagnosing residual cancer.

5. The method of claim 3 or 4 wherein a treatment protocol to be employed for a patient associated with the test set of biological cells is determined based on the diagnosis.

6. The method of claim 1 or 2, the method further comprising: diagnosing cancer based on the superimposed graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the defined normal cell population.

7. The method of claim 6, the method further comprising: determining a treatment protocol to be employed for a patient associated with the test set of cells based on the diagnosis.

8. The method of any of claims 1-7, wherein the staining of cells using the first protocol comprises exposing the cells to the following antibody combinations:FITC None; PE None, PerCP CD45, and APC CD34;FITC HLA-DR, PE CD1 lb, PerCP CD45, and APC CD34;FITC CD5, PE CD 19, PerCP CD45, and APC CD34;FITC CD 10, PE CD38, PerCP CD45, and APC CD34;FITC CD38, PE CD117, PerCP CD45, and APC CD34;FITC CD16, PE CD13, PerCP CD45, and APC CD34;FITC CD14, PE CD33, PerCP CD45, and APC CD34;FITC CD36, PE CD64, PerCP CD45, and APC CD34;FITC HLA-DR, PE CD123, PerCP CD45, and APC CD34; andFITC CD7, PE CD56, PerCP CD45, and APC CD34,where FITC is fluorescein isothiocyanate, PE is R Phycoerythrin, PerCP is Peridinin Chlorophyl Protein, and APC is Allophycocyanin.

9. The method of any of claims 1-8, wherein a number of the multiple types of cells is 23 types of cells.

10. The method of any of claims 1-8, wherein a number of the multiple types of cells is 24 types of cells.

11. The method of any of claims 1-10, wherein a type of cell corresponds to: a lineage of the cell;a maturation stage of the cell; orcombinations thereof.

12. The method of any of claims 1-11, wherein the types of cells of the multiple types of cells include:Hematopoietic Stem Cells (HSC);Common Progenitor Cells;Mast Cells;Basophils;Plasmocytic Dendritic Cells;Erythroblasts;Eosinophils (EOS);Monocyte 1;Monocyte 2;Nucleated Red Blood Cells (N RBC);Granular Blasts Cells (Myeloid Progenitor Cells);Promyelocytes Cells (Stage 2 Maturing Myeloid Cells);Myelocytes (Stage 3 Maturing Myeloid Cells);Metamyelocytes >Bands cells (Stage 4 Maturing Myeloid Cells);Neutrophils (Mature Neutrophils);B Lymphoid Progenitor Cells 1;B Lymphoid Progenitor Cells 2;B Lymphoid Progenitor Cells 3;Mature Lymphocytes NK;Mature Lymphocytes B;Mature Lymphocytes T;Plasma Cells; orcombinations thereof.

13. The method of any of claims 1-11, wherein the types of cells of the multiple types of cells include:Hematopoietic Stem Cells (HSC);Common Progenitor Cells;Mast Cells;Basophil;Plasmocytic Dendritic Cells;Erythroid Precursors;Early Erythroid Cells;Nucleated Red Blood Cells (N RBC);Eosinophils (EOS);Monocyte 1;Monocyte 2;Myeloid Progenitors;Stage 2 Immature Neutrophils;Stage 3 Immature Neutrophils;Stage 4 Immature Neutrophils;Neutrophils;B Lymphoid Progenitor 1;B Lymphoid Progenitor 2;B Lymphoid Progenitor 3;Mature Lymphocytes;Mature Lymphocytes NK;Mature Lymphocytes B;Mature Lymphocytes T;Plasma cells; orcombinations thereof.

14. The method of any of claims 1-13, wherein a position in the graphical representation of the normal cell population along a horizontal axis is an indicator of a cell maturation level.

15. The method of any of claims 1-14, wherein a position in the graphical representation of the normal cell population along a vertical axis is an indicator of a cell maturation level.

16. The method of any of claims 1-15, wherein the graphical representation of the normal cell population includes a vertical line representing a transition in the representation between cell types which are CD34 positive and cell types which are CD34 negative.

17. The method of any of claims 1-16, wherein the graphical representation of the normal cell population includes percentage indicators for one or more of the cell populations or groups of cell populations.

18. The method of any of claims 1-17, wherein the graphical representation of the normal cell population uses color to distinguish different types of cell.

19. The method of any of claims 1-18, wherein superimposing the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population includes using color to indicate cancer cells in the cells of the test set of biological cells.

20. The method of any of claims 1-19, wherein superimposing the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population includes:underfilling an area of a normal cell type to indicate a number of the type of cell in the test set of biological cells is less than the determined mean number of the type of cell for the plurality of sets of normal cells;overfilling an area of a normal cell type to indicate a number of the type of cell in the test set of biological cells is larger than the determined mean number of the type of cell for the plurality of sets of normal cells; orcombinations thereof.

21. The method of any of claims 1-20, comprising:detecting an indication of the presence of one or more types of cancer based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population;detecting an indication of the absence of cancer based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population;detecting an indication of a stage of recovery based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population;detecting an indication of a response to treatment based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population; or combinations thereof.

22. The method of any of claims 1-21, comprising:determining a treatment protocol to be employed for a patient associated with the test set of biological cells based on the superimposing of the graphical representation of the classification of the cells of the test set of biological cells onto the graphical representation of the normal cell population.

23. The method of claim 22, wherein the determined treatment protocol includes:no treatment;waiting;monitoring;chemotherapy;radiation treatment; orcombinations thereof.

24. The method of any of claims 1-23, wherein the determining for each set of the plurality of sets of normal cells, a respective number of cells of multiple types of cells in the set of normal cells comprises using gating to classify the cells stained using the first protocol.

25. The method of any of claims 1-24, comprising using the gating to classify cells in the test set of biological cells.

26. The method of claims 24 or 25, wherein,the gating is set based on user input;the gating is set using a processing agent; orthe gating is set using a processing agent in combination with user input.

27. The method of claim 24, wherein,the processing agent uses statistical clustering techniques to set the gating; the processing agent uses Support Vector Machines (SVMs) to set the gating; or the processing agent uses statistical clustering techniques and SVMs to set the gating.

28. The method of any of claims 1-27, comprising:flagging the test data set as indicating normal marrow based on the classifying of each cell in the test set of biological cells;flagging the test data set as indicating abnormal marrow based on the classifying of each cell in the test set of biological cells;flagging the test data set for review; orcombinations thereof.

29. The method of any of claims 1-28, comprising:flagging the test data set of cells for review.

30. The method of claim 29, comprising:flagging the test data set of cells for review in response to an indication the staining is inconsistent with staining using the first protocol;flagging the test data set of cells for review in response to an indication analysis of the cells of the test set of cells was performed incorrectly;flagging the test data set of cells for review in response to an indication the test set of cells includes an insufficient number of cells;flagging the test data set of cells for review in response to an indication the test set of cells was improperly collected; orcombinations thereof.

31. A diagnostic system comprising:one or more memories; andsignal processing circuitry coupled to the one or more memories, wherein the signal processing circuitry, in operation, implements a method according to any of claims 1 to 30.

32. A non-transitory computer-readable medium having contents which configure a processing system to perform a method according to any of claims 1-30.